menu
    • menu
    [{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"IOV-3001","moa":"IL-2","graph1":"Oncology","graph2":"Preclinical","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Iovance Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avid Bioservices \/ Iovance Biotherapeutics"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Bioservices \/ Oragenics"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Mapp Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Human monoclonal antiviral antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Avid Bioservices \/ Avid Bioservices","highestDevelopmentStatusID":"5","companyTruncated":"Avid Bioservices \/ Avid Bioservices"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"GCSF","graph1":"Immunology","graph2":"Phase III","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Avid Bioservices \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Avid Bioservices \/ Humanigen"}]

    Find Clinical Drug Pipeline Developments & Deals by Avid Bioservices

    Menu

    Avid Bioservices

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

                            Details : This collaboration enhances commercial production efforts for lenzilumab in advance of potential filings for emergency use authorization (EUA) and subsequent Biologics License Application (BLA) later this year.

                            Brand Name : Humaneered

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 03, 2021

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Humanigen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human monoclonal antiviral antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Mapp Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal A...

                            Details : Mapp Biopharmaceutical has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phas...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 26, 2020

                            Lead Product(s) : Human monoclonal antiviral antibody

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Mapp Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terra CoV-2 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Oragenics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

                            Details : Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenics’ novel SARS CoV-2 (COVID-19) spike protein vaccine candidate...

                            Brand Name : Terra CoV-2

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 20, 2020

                            Lead Product(s) : Terra CoV-2 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Oragenics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avid Bioservices

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IOV-3001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of...

                            Details : Iovance Biotherapeutics has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.

                            Brand Name : IOV-3001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 06, 2020

                            Lead Product(s) : IOV-3001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Iovance Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth